Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
- PMID: 11967536
- DOI: 10.1038/ng879
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
Abstract
Mutations in BRCA1 and BRCA2 confer a high risk of breast and ovarian cancer, but account for only a small fraction of breast cancer susceptibility. To find additional genes conferring susceptibility to breast cancer, we analyzed CHEK2 (also known as CHK2), which encodes a cell-cycle checkpoint kinase that is implicated in DNA repair processes involving BRCA1 and p53 (refs 3,4,5). We show that CHEK2(*)1100delC, a truncating variant that abrogates the kinase activity, has a frequency of 1.1% in healthy individuals. However, this variant is present in 5.1% of individuals with breast cancer from 718 families that do not carry mutations in BRCA1 or BRCA2 (P = 0.00000003), including 13.5% of individuals from families with male breast cancer (P = 0.00015). We estimate that the CHEK2(*)1100delC variant results in an approximately twofold increase of breast cancer risk in women and a tenfold increase of risk in men. By contrast, the variant confers no increased cancer risk in carriers of BRCA1 or BRCA2 mutations. This suggests that the biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same pathway.
Comment in
-
CHEKs and balances: accounting for breast cancer.Nat Genet. 2002 May;31(1):3-4. doi: 10.1038/ng0502-3. Nat Genet. 2002. PMID: 11984555 No abstract available.
Similar articles
-
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.Cancer Res. 2003 Dec 1;63(23):8153-7. Cancer Res. 2003. PMID: 14678969
-
BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.Breast Cancer Res Treat. 2008 Jul;110(1):161-7. doi: 10.1007/s10549-007-9689-2. Epub 2007 Jul 28. Breast Cancer Res Treat. 2008. PMID: 17661168
-
Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.Isr Med Assoc J. 2007 Nov;9(11):791-6. Isr Med Assoc J. 2007. PMID: 18085035
-
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. J Clin Oncol. 2008. PMID: 18172190 Review.
-
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.Oncogene. 2006 Sep 25;25(43):5837-45. doi: 10.1038/sj.onc.1209875. Oncogene. 2006. PMID: 16998498 Review.
Cited by
-
CHEK2 contribution to hereditary breast cancer in non-BRCA families.Breast Cancer Res. 2011;13(6):R119. doi: 10.1186/bcr3062. Epub 2011 Nov 24. Breast Cancer Res. 2011. PMID: 22114986 Free PMC article.
-
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z. Fam Cancer. 2015. PMID: 26026974
-
Invasive ductal breast carcinoma underneath a lipoma in a male patient.J Clin Aesthet Dermatol. 2012 Oct;5(10):33-7. J Clin Aesthet Dermatol. 2012. PMID: 23125888 Free PMC article.
-
Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.Mol Biol Rep. 2016 Nov;43(11):1273-1284. doi: 10.1007/s11033-016-4061-4. Epub 2016 Aug 29. Mol Biol Rep. 2016. PMID: 27573125
-
CHEK2 mutations and papillary thyroid cancer: correlation or coincidence?Hered Cancer Clin Pract. 2022 Jan 31;20(1):5. doi: 10.1186/s13053-022-00211-7. Hered Cancer Clin Pract. 2022. PMID: 35101071 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
